Expression of vascular endothelial growth factor in patients with triple negative breast cancer in China and its relation to clinicopathologic features: a meta-analysis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

DENG Feng , Adilijiang·Maimaitiming , YANG Shuyi ,  Dilimulati·Aisimutula

Department of Breast Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, P.R.China;

Corresponding?author：

Dilimulati·Aisimutula, Email: 2499156828@qq.com

Keywords：

triple negative breast cancer; vascular endothelial growth factor; meta-analysis

DOI：

10.7507/1007-9424.201701020

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically evaluate expression of vascular endothelial growth factor (VEGF) protein in triple negative breast cancer (TNBC) and analyze its correlation between positive expression of VEGF protein and clinicopathologic features of patient with TNBC. Methods The published literatures relevant VEGF protein expression in TNBC and its relation to clinicopathologic features of patient with TNBC in China were retrieved by means of CNKI, Wanfang, VIP, China Biomedical, Chaoxing Medalink, PubMed databases, and other search tools. The literatures were independently filtered, extracted, and assessed by two reviewers according to the inclusion criteria and exclusion criteria. The meta-analysis was conducted by using RevMan 5.3 software. Results A total of 11 literatures were included and involved 1 838 patients (750 patients in the TNBC group and 1 088 patients in the non-TNBC group). The results of meta-nalysis showed that the positive expression of VEGF protein in the TNBC group was significantly higher than that in the non-TNBC group 〔OR=2.64, 95%CI (2.14, 3.26), P<0.000 01〕 , which was significantly increased in the TNBC patients with positive lymph node or stage Ⅲ–Ⅳ as compared with the negative lymph node or stage Ⅰ–Ⅱ 〔OR=0.30, 95% CI (0.14, 0.46), P=0.000 2; OR=0.43, 95% CI (0.29, 0.62), P<0.000 01〕 . However, the positive expression of VEGF protein was no associated with the age of patients with TNBC or tumor size (P>0.05). Conclusions VEGF highly expresses in TNBC and it is expected to be a new therapeutic target. Positive expression of VEGF protein is related to positive lymph node and late TNM stage, and it might be associated with prognosis of patient with TNBC.

Citation： DENG Feng, Adilijiang·Maimaitiming, YANG Shuyi, Dilimulati·Aisimutula. Expression of vascular endothelial growth factor in patients with triple negative breast cancer in China and its relation to clinicopathologic features: a meta-analysis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2017, 24(8): 992-999. doi: 10.7507/1007-9424.201701020 Copy

1.	陳萬青, 鄭榮壽, 曾紅梅, 等. 2011 年中國惡性腫瘤發病和死亡分析. 中國腫瘤, 2015, 24(1): 1-10.
2.	Metzger-Filho O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol, 2012, 30(15): 1879-1887.
3.	Bae YH, Ryu JH, Park HJ, et al. Mutant p53-Notch1 signaling axis is involved in curcumin-induced apoptosis of breast cancer cells. Korean J Physiol Pharmacol, 2013, 17(4): 291-297.
4.	Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer, 2012, 118(22): 5463-5472.
5.	Barbieri V, Sanpaolo P, Genovesi D. Prognostic impact of triple negative phenotype in conservatively treated breast cancer. Breast J, 2011, 17(4): 377-382.
6.	張美芳. NF-κB、COX-2 和 VEGF 在三陰性乳腺癌中的表達、相關性及臨床意義. 蘇州大學, 2014: 1-40.
7.	孫潔. VEGF 表達及微血管密度與三陰性乳腺癌及非三陰性乳腺癌臨床病理特征的關系. 廣西醫科大學, 2010: 1-55.
8.	左麗, 徐迎春, 李綱, 等. VEGF 在三陰性乳腺癌中的表達及臨床意義研究. 世界最新醫學信息文摘, 2015, 15(66): 1-2.
9.	謝閔, 許增祥, 孫圣榮. 環氧化物酶-2、血管內皮生長因子、拓撲異構酶 Ⅱ 在三陰性乳腺癌中的表達及臨床意義. 中華實驗外科雜志, 2014, 31(8): 1799-1801.
10.	馬濤, 陸肖瑋, 丁云. 三陰性乳腺癌 COX-2, VEGF 表達相關性及臨床意義研究. 中國腫瘤外科雜志, 2012, 4(3): 145-148.
11.	史曉宇, 賈倩, 劉婷, 等. 三陰性乳腺癌中 VEGF、Ki-67 的表達及臨床意義. 實用腫瘤雜志, 2016, 31(1): 35-38.
12.	蔣洪棉, 朱世龍, 李辛辛, 等. 三陰性乳腺癌中的 VEGF 表達及臨床意義. 廣西醫學, 2013, 35(6): 743-744.
13.	管小青, 鄭向欣, 吳驥, 等. 三陰性乳腺癌組織中 MMP-3 和 VEGF 表達的相關性及臨床分析. 中國普外基礎與臨床雜志, 2014, 21(5): 567-571.
14.	袁媛, 張耀龍. 三陰性乳腺癌組織中 VEGF 的表達及其意義. 西部醫學, 2014, 26(5): 606-607.
15.	趙筱倩, 陸肖瑋. 血管內皮生長因子在三陰性乳腺癌中表達的臨床價值分析. 醫學理論與實踐, 2016, 29(16): 2157-2158.
16.	譚林深, 秦海明, 樸瑛, 等. 異黏蛋白和血管內皮生長因子蛋白在三陰性乳腺癌組織中的表達及其臨床意義. 中華腫瘤雜志, 2015, 37(11): 827-832.
17.	Zhang Y, Xu S, Lin J, et al. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo. Breast Cancer Res Treat, 2012, 136(2): 379-388.
18.	Valdehita A, Carmena MJ, Bajo AM, et al. RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Mol Cell Endocrinol, 2012, 348(1): 241-246.
19.	Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med, 2006, 12(8): 895-904.
20.	Cook MT, Liang Y, Besch-Williford C, et al. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells. Breast Cancer (Dove Med Press), 2016, 9: 9-19.
21.	Roberti MP, Arriaga JM, Bianchini M, et al. Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther, 2012, 13(11): 1123-1140.
22.	Linderholm BK, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol, 2009, 20(10): 1639-1646.
23.	Zhao D, Pan C, Sun J, et al. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene, 2015, 34(24): 3107-3119.
24.	李紫瑤, 王淑梅, 王平, 等. VEGF 表達及微血管密度、淋巴管密度與三陰性乳腺癌及非三陰性乳腺癌臨床病理特征的關系. 北京: 首都醫科大學超聲科學系第一屆超聲醫學學術大會, 2014: 144-145.

1. 陳萬青, 鄭榮壽, 曾紅梅, 等. 2011 年中國惡性腫瘤發病和死亡分析. 中國腫瘤, 2015, 24(1): 1-10.
2. Metzger-Filho O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol, 2012, 30(15): 1879-1887.
3. Bae YH, Ryu JH, Park HJ, et al. Mutant p53-Notch1 signaling axis is involved in curcumin-induced apoptosis of breast cancer cells. Korean J Physiol Pharmacol, 2013, 17(4): 291-297.
4. Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer, 2012, 118(22): 5463-5472.
5. Barbieri V, Sanpaolo P, Genovesi D. Prognostic impact of triple negative phenotype in conservatively treated breast cancer. Breast J, 2011, 17(4): 377-382.
6. 張美芳. NF-κB、COX-2 和 VEGF 在三陰性乳腺癌中的表達、相關性及臨床意義. 蘇州大學, 2014: 1-40.
7. 孫潔. VEGF 表達及微血管密度與三陰性乳腺癌及非三陰性乳腺癌臨床病理特征的關系. 廣西醫科大學, 2010: 1-55.
8. 左麗, 徐迎春, 李綱, 等. VEGF 在三陰性乳腺癌中的表達及臨床意義研究. 世界最新醫學信息文摘, 2015, 15(66): 1-2.
9. 謝閔, 許增祥, 孫圣榮. 環氧化物酶-2、血管內皮生長因子、拓撲異構酶 Ⅱ 在三陰性乳腺癌中的表達及臨床意義. 中華實驗外科雜志, 2014, 31(8): 1799-1801.
10. 馬濤, 陸肖瑋, 丁云. 三陰性乳腺癌 COX-2, VEGF 表達相關性及臨床意義研究. 中國腫瘤外科雜志, 2012, 4(3): 145-148.
11. 史曉宇, 賈倩, 劉婷, 等. 三陰性乳腺癌中 VEGF、Ki-67 的表達及臨床意義. 實用腫瘤雜志, 2016, 31(1): 35-38.
12. 蔣洪棉, 朱世龍, 李辛辛, 等. 三陰性乳腺癌中的 VEGF 表達及臨床意義. 廣西醫學, 2013, 35(6): 743-744.
13. 管小青, 鄭向欣, 吳驥, 等. 三陰性乳腺癌組織中 MMP-3 和 VEGF 表達的相關性及臨床分析. 中國普外基礎與臨床雜志, 2014, 21(5): 567-571.
14. 袁媛, 張耀龍. 三陰性乳腺癌組織中 VEGF 的表達及其意義. 西部醫學, 2014, 26(5): 606-607.
15. 趙筱倩, 陸肖瑋. 血管內皮生長因子在三陰性乳腺癌中表達的臨床價值分析. 醫學理論與實踐, 2016, 29(16): 2157-2158.
16. 譚林深, 秦海明, 樸瑛, 等. 異黏蛋白和血管內皮生長因子蛋白在三陰性乳腺癌組織中的表達及其臨床意義. 中華腫瘤雜志, 2015, 37(11): 827-832.
17. Zhang Y, Xu S, Lin J, et al. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo. Breast Cancer Res Treat, 2012, 136(2): 379-388.
18. Valdehita A, Carmena MJ, Bajo AM, et al. RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Mol Cell Endocrinol, 2012, 348(1): 241-246.
19. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med, 2006, 12(8): 895-904.
20. Cook MT, Liang Y, Besch-Williford C, et al. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells. Breast Cancer (Dove Med Press), 2016, 9: 9-19.
21. Roberti MP, Arriaga JM, Bianchini M, et al. Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther, 2012, 13(11): 1123-1140.
22. Linderholm BK, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol, 2009, 20(10): 1639-1646.
23. Zhao D, Pan C, Sun J, et al. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene, 2015, 34(24): 3107-3119.
24. 李紫瑤, 王淑梅, 王平, 等. VEGF 表達及微血管密度、淋巴管密度與三陰性乳腺癌及非三陰性乳腺癌臨床病理特征的關系. 北京: 首都醫科大學超聲科學系第一屆超聲醫學學術大會, 2014: 144-145.

Previous Article
Effectiveness and safety analyses of electronic choledochoscopy in treatment of intrahepatic bile duct stones

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expression of vascular endothelial growth factor in patients with triple negative breast cancer in China and its relation to clinicopathologic features: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content